{
  "symbol": "JNJ",
  "year": 2022,
  "Period": "Y2022",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2296,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.119
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Index to Audited Consolidated Financial Statements 41 Consolidated Balance Sheets 42 Consolidated Statements of Earnings 43 Consolidated Statements of Comprehensive Income 44 Consolidated Statements of Equity 45 Consolidated Statements of Cash Flows 47 Notes to Consolidated Financial Statements 103 Report of Independent Registered Public Accounting Firm (PCAOB ID 238 ) 106 Management\u2019s Report on Internal Control Over Financial Reporting 40 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS At January\u00a02, 2022 and January\u00a03, 2021 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2021 2020 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 14,487 13,985 Marketable securities (Notes\u00a01 and 2) 17,121 11,200 Accounts receivable trade, less allowances for doubtful accounts $ 230 (2020, $ 293 ) 15,283 13,576 Inventories (Notes\u00a01 and 3) 10,387 9,344 Prepaid expenses and other receivables 3,701 3,132 Total current assets 60,979 51,237 Property, plant and equipment, net (Notes\u00a01 and 4) 18,962 18,766 Intangible assets, net (Notes\u00a01 and 5) 46,392 53,402 Goodwill (Notes\u00a01 and 5) 35,246 36,393 Deferred taxes on income (Note 8) 10,223 8,534 Other assets 10,216 6,562 Total assets $ 182,018 174,894 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 3,766 2,631 Accounts payable 11,055 9,505 Accrued liabilities 13,612 13,968 Accrued rebates, returns and promotions 12,095 11,513 Accrued compensation and employee related obligations 3,586 3,484 Accrued taxes on income (Note 8) 1,112 1,392 Total current liabilities 45,226 42,493 Long-term debt (Note\u00a07) 29,985 32,635 Deferred taxes on income (Note 8) 7,487 7,214 Employee related obligations (Notes\u00a09 and 10) 8,898 10,771 Long-term taxes payable (Note 1) 5,713 6,559 Other liabilities 10,686 11,944 Total liabilities 107,995 111,616 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 13,058 ) ( 15,242 ) Retained earnings 123,060 113,890 113,122 101,768 Less: common stock held in treasury, at cost (Note\u00a012) ( 490,878,000 shares and 487,331,000 shares) 39,099 38,490 Total shareholders\u2019 equity 74,023 63,278 Total liabilities and shareholders\u2019 equity $ 182,018 174,894 See Notes to Consolidated Financial Statements 41 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2021 2020 2019 Sales to customers $ 93,775 82,584 82,059 Cost of products sold 29,855 28,427 27,556 Gross profit 63,920 54,157 54,503 Selling, marketing and administrative expenses 24,659 22,084 22,178 Research and development expense 14,714 12,159 11,355 In-process research and development (Note 5) 900 181 890 Interest income ( 53 ) ( 111 ) ( 357 ) Interest expense, net of portion capitalized (Note\u00a04) 183 201 318 Other (income) expense, net 489 2,899 2,525 Restructuring (Note 20) 252 247 266 Earnings before provision for taxes on income 22,776 16,497 17,328 Provision for taxes on income (Note\u00a08) 1,898 1,783 2,209 Net earnings $ 20,878 14,714 15,119 Net earnings per share (Notes 1 and 15) Basic $ 7.93 5.59 5.72 Diluted $ 7.81 5.51 5.63 Average shares outstanding (Notes 1 and 15) Basic 2,632.1 2,632.8 2,645.1 Diluted 2,674.0 2,670.7 2,684.3 See Notes to Consolidated Financial Statements 42 JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Dollars in Millions) (Note\u00a01) 2021 2020 2019 Net earnings $ 20,878 14,714 15,119 Other comprehensive income (loss), net of tax Foreign currency translation ( 1,079 ) ( 233 ) 164 Securities: Unrealized holding gain (loss) arising during period ( 4 ) 1 \u2014 Reclassifications to earnings \u2014 \u2014 \u2014 Net change ( 4 ) 1 \u2014 Employee benefit plans: Prior service credit (cost), net of amortization ( 169 ) 1,298 ( 18 ) Gain (loss), net of amortization 4,318 ( 1,135 ) ( 714 ) Effect of exchange rates 106 ( 229 ) ( 1 ) Net change 4,255 ( 66 ) ( 733 ) Derivatives & hedges: Unrealized gain (loss) arising during period ( 199 ) 1,000 ( 107 ) Reclassifications to earnings ( 789 ) ( 53 ) 7 Net change ( 988 ) 947 ( 100 ) Other comprehensive income (loss) 2,184 649 ( 669 ) Comprehensive income $ 23,062 15,363 14,450 The tax effects in other comprehensive income for the fiscal years 2021, 2020 and 2019 respectively: Foreign Currency Translation; $ 346 million, $ 536 million and $ 19 million; Securities: $ 1 million in 2021, Employee Benefit Plans: $ 1,198 million, $ 21 million and $ 222 million, Derivatives & Hedges: $ 263 million, $ 252 million and $ 27 million.",
      "score": 0.9967
    },
    {
      "sent": "Risks and uncertainties include, but are not limited to: Risks Related to Product Development, Market Success and Competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties.",
      "score": 0.9962
    },
    {
      "sent": "Risks Related to the Company\u2019s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally \nTrends and the Planned Separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; \u2022 The Company\u2019s ability to consummate the planned separation of the Company\u2019s Consumer Health business on a timely basis or at all; \u2022 The Company\u2019s ability to successfully separate the Company\u2019s Consumer Health business and realize the anticipated benefits from the planned separation; and \u2022 The New Consumer Health Company\u2019s ability to succeed as a standalone publicly traded company.",
      "score": 0.9758
    }
  ],
  "top_negative": [
    {
      "sent": "Key products in the Pharmaceutical segment include: REMICADE \u00ae (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI \u00ae (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA \u00ae (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA \u00ae (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA \u00ae (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; the Janssen COVID-19 vaccine, authorized for use under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older; EDURANT \u00ae (rilpivirine), PREZISTA \u00ae (darunavir) and PREZCOBIX \u00ae /REZOLSTA \u00ae (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA \u00ae (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA \u00ae (methylphenidate HCl) extended-release tablets CII, a treatment 1 for attention deficit hyperactivity disorder; INVEGA SUSTENNA \u00ae /XEPLION \u00ae (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA \u00ae /TREVICTA \u00ae (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA \u00ae for at least four months; RISPERDAL CONSTA \u00ae (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA \u00ae (abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA \u00ae (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA \u00ae (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX \u00ae (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO \u00ae (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis;  PROCRIT \u00ae /EPREX \u00ae (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease; XARELTO \u00ae (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; INVOKANA \u00ae (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET \u00ae /VOKANAMET \u00ae (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET \u00ae XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT \u00ae (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI \u00ae (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH.",
      "score": -0.9201
    },
    {
      "sent": "Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.",
      "score": -0.8658
    },
    {
      "sent": "Risks Related to Economic Conditions, Financial Markets and Operating Internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; \u2022 The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.",
      "score": -0.8519
    }
  ],
  "forward_snippets": [
    "Employees worldwide are further guided by the Company\u2019s Code of Business Conduct which sets basic requirements for business conduct and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates.",
    "The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies.",
    "Therefore, we encourage investors and others interested in the Company to review the information posted\nguidance on expected employee behaviors in every market where it operates.",
    "The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies.",
    "The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies."
  ],
  "curated_text": "Symbol: JNJ. Year: 2022. Period: Y2022. ReportType: K10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Index to Audited Consolidated Financial Statements 41 Consolidated Balance Sheets 42 Consolidated Statements of Earnings 43 Consolidated Statements of Comprehensive Income 44 Consolidated Statements of Equity 45 Consolidated Statements of Cash Flows 47 Notes to Consolidated Financial Statements 103 Report of Independent Registered Public Accounting Firm (PCAOB ID 238 ) 106 Management\u2019s Report on Internal Control Over Financial Reporting 40 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS At January\u00a02, 2022 and January\u00a03, 2021 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2021 2020 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 14,487 13,985 Marketable securities (Notes\u00a01 and 2) 17,121 11,200 Accounts receivable trade, less allowances for doubtful accounts $ 230 (2020, $ 293 ) 15,283 13,576 Inventories (Notes\u00a01 and 3) 10,387 9,344 Prepaid expenses and other receivables 3,701 3,132 Total current assets 60,979 51,237 Property, plant and equipment, net (Notes\u00a01 and 4) 18,962 18,766 Intangible assets, net (Notes\u00a01 and 5) 46,392 53,402 Goodwill (Notes\u00a01 and 5) 35,246 36,393 Deferred taxes on income (Note 8) 10,223 8,534 Other assets 10,216 6,562 Total assets $ 182,018 174,894 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 3,766 2,631 Accounts payable 11,055 9,505 Accrued liabilities 13,612 13,968 Accrued rebates, returns and promotions 12,095 11,513 Accrued compensation and employee related obligations 3,586 3,484 Accrued taxes on income (Note 8) 1,112 1,392 Total current liabilities 45,226 42,493 Long-term debt (Note\u00a07) 29,985 32,635 Deferred taxes on income (Note 8) 7,487 7,214 Employee related obligations (Notes\u00a09 and 10) 8,898 10,771 Long-term taxes payable (Note 1) 5,713 6,559 Other liabilities 10,686 11,944 Total liabilities 107,995 111,616 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 13,058 ) ( 15,242 ) Retained earnings 123,060 113,890 113,122 101,768 Less: common stock held in treasury, at cost (Note\u00a012) ( 490,878,000 shares and 487,331,000 shares) 39,099 38,490 Total shareholders\u2019 equity 74,023 63,278 Total liabilities and shareholders\u2019 equity $ 182,018 174,894 See Notes to Consolidated Financial Statements 41 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2021 2020 2019 Sales to customers $ 93,775 82,584 82,059 Cost of products sold 29,855 28,427 27,556 Gross profit 63,920 54,157 54,503 Selling, marketing and administrative expenses 24,659 22,084 22,178 Research and development expense 14,714 12,159 11,355 In-process research and development (Note 5) 900 181 890 Interest income ( 53 ) ( 111 ) ( 357 ) Interest expense, net of portion capitalized (Note\u00a04) 183 201 318 Other (income) expense, net 489 2,899 2,525 Restructuring (Note 20) 252 247 266 Earnings before provision for taxes on income 22,776 16,497 17,328 Provision for taxes on income (Note\u00a08) 1,898 1,783 2,209 Net earnings $ 20,878 14,714 15,119 Net earnings per share (Notes 1 and 15) Basic $ 7.93 5.59 5.72 Diluted $ 7.81 5.51 5.63 Average shares outstanding (Notes 1 and 15) Basic 2,632.1 2,632.8 2,645.1 Diluted 2,674.0 2,670.7 2,684.3 See Notes to Consolidated Financial Statements 42 JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Dollars in Millions) (Note\u00a01) 2021 2020 2019 Net earnings $ 20,878 14,714 15,119 Other comprehensive income (loss), net of tax Foreign currency translation ( 1,079 ) ( 233 ) 164 Securities: Unrealized holding gain (loss) arising during period ( 4 ) 1 \u2014 Reclassifications to earnings \u2014 \u2014 \u2014 Net change ( 4 ) 1 \u2014 Employee benefit plans: Prior service credit (cost), net of amortization ( 169 ) 1,298 ( 18 ) Gain (loss), net of amortization 4,318 ( 1,135 ) ( 714 ) Effect of exchange rates 106 ( 229 ) ( 1 ) Net change 4,255 ( 66 ) ( 733 ) Derivatives & hedges: Unrealized gain (loss) arising during period ( 199 ) 1,000 ( 107 ) Reclassifications to earnings ( 789 ) ( 53 ) 7 Net change ( 988 ) 947 ( 100 ) Other comprehensive income (loss) 2,184 649 ( 669 ) Comprehensive income $ 23,062 15,363 14,450 The tax effects in other comprehensive income for the fiscal years 2021, 2020 and 2019 respectively: Foreign Currency Translation; $ 346 million, $ 536 million and $ 19 million; Securities: $ 1 million in 2021, Employee Benefit Plans: $ 1,198 million, $ 21 million and $ 222 million, Derivatives & Hedges: $ 263 million, $ 252 million and $ 27 million. Risks and uncertainties include, but are not limited to: Risks Related to Product Development, Market Success and Competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties. Risks Related to the Company\u2019s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally \nTrends and the Planned Separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; \u2022 The Company\u2019s ability to consummate the planned separation of the Company\u2019s Consumer Health business on a timely basis or at all; \u2022 The Company\u2019s ability to successfully separate the Company\u2019s Consumer Health business and realize the anticipated benefits from the planned separation; and \u2022 The New Consumer Health Company\u2019s ability to succeed as a standalone publicly traded company. Top negative sentences: Key products in the Pharmaceutical segment include: REMICADE \u00ae (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI \u00ae (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA \u00ae (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA \u00ae (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA \u00ae (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; the Janssen COVID-19 vaccine, authorized for use under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older; EDURANT \u00ae (rilpivirine), PREZISTA \u00ae (darunavir) and PREZCOBIX \u00ae /REZOLSTA \u00ae (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA \u00ae (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA \u00ae (methylphenidate HCl) extended-release tablets CII, a treatment 1 for attention deficit hyperactivity disorder; INVEGA SUSTENNA \u00ae /XEPLION \u00ae (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA \u00ae /TREVICTA \u00ae (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA \u00ae for at least four months; RISPERDAL CONSTA \u00ae (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA \u00ae (abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA \u00ae (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA \u00ae (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX \u00ae (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO \u00ae (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis;  PROCRIT \u00ae /EPREX \u00ae (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease; XARELTO \u00ae (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; INVOKANA \u00ae (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET \u00ae /VOKANAMET \u00ae (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET \u00ae XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT \u00ae (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI \u00ae (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Risks Related to Economic Conditions, Financial Markets and Operating Internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; \u2022 The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets. Forward-looking snippets: Employees worldwide are further guided by the Company\u2019s Code of Business Conduct which sets basic requirements for business conduct and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies. Therefore, we encourage investors and others interested in the Company to review the information posted\nguidance on expected employee behaviors in every market where it operates. The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies. The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies."
}